Roche/Genentech CMO Levi Garraway

ASH: Roche's an­ti­body-drug con­ju­gate Po­livy added to chemo-an­ti­body com­bo boosts sur­vival in ear­ly-stage lym­phoma

Break­throughs in drug de­vel­op­ment have be­gun to un­lock the po­ten­tial of an­ti­body-drug con­ju­gates, ther­a­pies de­signed to bet­ter tar­get pro­teins on tu­mor cells. Genen­tech’s Po­livy has be­come an ear­ly win­ner in blood can­cer, and now the drug­mak­er is re­veal­ing promis­ing re­sults in get­ting in­to pa­tients even soon­er.

A com­bi­na­tion of Roche’s Po­livy, an ADC tar­get­ing the CD79b pro­tein on tu­mor cells, with Rit­ux­an and the chemother­a­py reg­i­men R-CHOP cut the risk of dis­ease pro­gres­sion or death over Rit­ux­an-chemo alone by 27% in pa­tients with first-line dif­fuse large B cell lym­phoma, ac­cord­ing to late-break­ing da­ta pre­sent­ed Tues­day at #ASH21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.